Halozyme Therapeutics, Inc. beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $1.73 | $2.17 | +25.4% | Beat |
| Q12026 FY2026 | $1.46 | $1.48 | +1.4% | Beat |
| Q42025 FY2025 | $2.07 | — | — | Miss |
Back to HALO overview · HALO holders · HALO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.